Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
about
Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancerMarkers of resistance to anti-EGFR therapy in colorectal cancerG protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei--serpentine gateways to neuroendocrine homeostasisPhosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitorsEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabAssessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarrayAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASProfile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerPersonalized treatment for advanced colorectal cancer: KRAS and beyondMolecularly targeted drugs for metastatic colorectal cancerAre KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysisTissue distribution studies of protein therapeutics using molecular probes: molecular imagingMolecular pathology of lung cancer: key to personalized medicine.Theranostic applications of antibodies in oncology.EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersCetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signatureHER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cellsFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentExpression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer CellsAnti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cellsSmall is beautiful: insulin-like growth factors and their role in growth, development, and cancerCetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.Where now for anti-EGF receptor therapies in colorectal cancer?Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer.Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.Frequent activation of EGFR in advanced chordomas.Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer.The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
P2860
Q24243806-0FB40CBC-71DC-4A05-89DE-DBF75AE97E24Q24598640-6C1DC714-8FD4-444D-A875-7C93EE4AEA80Q24633335-F9AE40C5-646D-45EA-8C2A-9C4D57775228Q24644787-E27D161E-4657-4C20-B0A3-72E433E05CAEQ24652337-CC6473FB-07E4-479C-BDB2-A8DB135EBE6CQ24675853-82882F89-A6BF-43D0-9A19-E9EFBCA8B543Q26748924-2B8D9660-194E-46B2-B61E-182997673B9EQ26749012-3238613A-381F-4F47-A3A5-91342597553AQ26751344-E79AB022-1569-4942-8217-4752472DEFEAQ26766535-6F85757C-5D8F-422E-9329-D120BD329455Q26771952-6DE20025-CC3C-4959-A480-4C1F86C764E6Q26822817-1A79CB53-19D2-47B2-B807-79714590596DQ26828735-CD5FCC8B-3B75-4B5B-ACD0-537EFE7AB70EQ26828992-5C3A6594-3487-4683-8B8C-3080D9231144Q26865056-6A9F2672-D659-487A-8423-8F4B7FDC22F0Q26865516-0DFEC80E-EA5E-48A7-B7F0-5FB2CC53C192Q27691299-96D0EA2F-F7E1-4179-BE39-C0DBB0AFE6DFQ27693293-325B2E3A-3100-48E5-98EC-0D1A9BAE2D51Q27851583-3B39313C-0EE3-4072-8E75-BC2B73C7F482Q27852970-D0315C4E-5E7C-49CD-8DDE-8F04EAF9715EQ28076490-3B61CB13-14B8-4499-B400-C635CB539CF6Q28084216-E0A723BC-4351-489F-8279-CBC7B772B014Q28087333-5A4C8D58-9374-4141-8946-196F22639AD6Q28468648-F54893F2-C2B4-448D-BDFE-28FCDF189719Q28473274-93A01E7F-DB79-4565-8337-CAF9F10F748AQ28533949-358F463D-76FA-4C27-85F2-47CE2D9EAA05Q28534094-47CA6608-24F4-4C0C-ACE1-5BF90B997205Q28732763-AEA0E958-51E7-413C-81AC-3C4AAB994168Q30395770-35D700A0-2A5B-4073-A0B5-4708D84677BDQ30441575-DE990A38-0652-4908-A32B-5BBC72FD631BQ30838052-AE576930-5BC5-42B4-8730-407D34B18CF4Q31038305-C00FA189-85F1-4290-B1F3-2B4C7B4E6546Q31143290-3963FD40-438F-4863-9D9E-7D3B5FC50568Q33250432-B905B805-0082-46CB-8578-25C8109B0E93Q33274473-643FC5DA-FF7B-4F64-9207-FF240CA32AF1Q33359798-3859832D-7787-421E-ADCB-F17ED569DCE2Q33387432-B044C394-8A6B-4294-8847-A55C2C1D77ACQ33525226-96AB3F4E-6527-4135-8935-4630E2824460Q33556004-CD72127A-E3C1-4535-95EE-FF7F7070D59BQ33565294-C315DA2A-799B-42F6-BA46-A64ADE13748C
P2860
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@ast
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@en
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@nl
type
label
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@ast
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@en
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@nl
prefLabel
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@ast
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@en
Cetuximab shows activity in co ...... eptor by immunohistochemistry.
@nl
P2093
P921
P356
P1476
Cetuximab shows activity in co ...... ceptor by immunohistochemistry
@en
P2093
Archie Tse
Audrey Hamilton
Daniel Fridman
David P Kelsen
David S Klimstra
Deborah Schrag
Dorothy Pan
Gary K Schwartz
Ki Young Chung
Lawrence Schwartz
P304
P356
10.1200/JCO.2005.08.037
P407
P577
2005-01-27T00:00:00Z